Annual CFF
$26.63 M
-$98.11 M-78.65%
December 31, 2023
Summary
- As of February 8, 2025, MRNS annual cash flow from financing activities is $26.63 million, with the most recent change of -$98.11 million (-78.65%) on December 31, 2023.
- During the last 3 years, MRNS annual CFF has fallen by -$82.59 million (-75.62%).
- MRNS annual CFF is now -78.65% below its all-time high of $124.74 million, reached on December 31, 2022.
Performance
MRNS Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
-$1.93 M
+$15.77 M+89.12%
September 30, 2024
Summary
- As of February 8, 2025, MRNS quarterly cash flow from financing activities is -$1.93 million, with the most recent change of +$15.77 million (+89.12%) on September 30, 2024.
- Over the past year, MRNS quarterly CFF has stayed the same.
- MRNS quarterly CFF is now -102.04% below its all-time high of $94.14 million, reached on December 31, 2022.
Performance
MRNS Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
-$18.70 M
-$27.83 M-305.03%
September 30, 2024
Summary
- As of February 8, 2025, MRNS TTM cash flow from financing activities is -$18.70 million, with the most recent change of -$27.83 million (-305.03%) on September 30, 2024.
- Over the past year, MRNS TTM CFF has stayed the same.
- MRNS TTM CFF is now -115.00% below its all-time high of $124.74 million, reached on December 31, 2022.
Performance
MRNS TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
MRNS Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -78.7% | 0.0% | 0.0% |
| 3 y3 years | -75.6% | -102.0% | -115.0% |
| 5 y5 years | -36.8% | -102.0% | -115.0% |
MRNS Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -78.7% | at low | -102.0% | +89.1% | -115.0% | at low |
| 5 y | 5-year | -78.7% | at low | -102.0% | +89.1% | -115.0% | at low |
| alltime | all time | -78.7% | +1326.5% | -102.0% | +89.1% | -115.0% | at low |
Marinus Pharmaceuticals Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$1.93 M(-89.1%) | -$18.70 M(-305.0%) |
| Jun 2024 | - | -$17.70 M(-6986.4%) | $9.12 M(-66.3%) |
| Mar 2024 | - | $257.00 K(-61.1%) | $27.06 M(+1.6%) |
| Dec 2023 | $26.63 M(-78.7%) | $661.00 K(-97.4%) | $26.63 M(-77.8%) |
| Sep 2023 | - | $25.90 M(>+9900.0%) | $120.10 M(+28.2%) |
| Jun 2023 | - | $237.00 K(-236.2%) | $93.65 M(+0.2%) |
| Mar 2023 | - | -$174.00 K(-100.2%) | $93.43 M(-25.1%) |
| Dec 2022 | $124.74 M(+202.0%) | $94.14 M(<-9900.0%) | $124.74 M(+303.7%) |
| Sep 2022 | - | -$546.00 K(-4000.0%) | $30.90 M(-48.1%) |
| Jun 2022 | - | $14.00 K(-100.0%) | $59.52 M(-17.7%) |
| Mar 2022 | - | $31.13 M(>+9900.0%) | $72.35 M(+75.1%) |
| Dec 2021 | $41.31 M(-62.2%) | $297.00 K(-98.9%) | $41.31 M(-61.1%) |
| Sep 2021 | - | $28.08 M(+118.7%) | $106.10 M(+36.2%) |
| Jun 2021 | - | $12.84 M(>+9900.0%) | $77.92 M(-28.6%) |
| Mar 2021 | - | $96.00 K(-99.9%) | $109.19 M(-0.0%) |
| Dec 2020 | $109.22 M(+60.7%) | $65.09 M(<-9900.0%) | $109.22 M(-2.7%) |
| Sep 2020 | - | -$106.00 K(-100.2%) | $112.20 M(-0.1%) |
| Jun 2020 | - | $44.12 M(>+9900.0%) | $112.28 M(+64.7%) |
| Mar 2020 | - | $117.00 K(-99.8%) | $68.17 M(+0.3%) |
| Dec 2019 | $67.97 M(+61.4%) | $68.07 M(<-9900.0%) | $67.97 M(+61.1%) |
| Sep 2019 | - | -$18.00 K(<-9900.0%) | $42.20 M(-0.0%) |
| Jun 2019 | - | $0.00(-100.0%) | $42.22 M(-0.0%) |
| Mar 2019 | - | -$83.00 K(-100.2%) | $42.23 M(+0.3%) |
| Dec 2018 | $42.12 M | $42.30 M(>+9900.0%) | $42.12 M(>+9900.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2018 | - | $0.00(-100.0%) | $64.00 K(-99.9%) |
| Jun 2018 | - | $14.00 K(-107.3%) | $45.88 M(+0.3%) |
| Mar 2018 | - | -$193.00 K(-179.4%) | $45.76 M(-3.8%) |
| Dec 2017 | $47.59 M(-2292.0%) | $243.00 K(-99.5%) | $47.59 M(+2.5%) |
| Sep 2017 | - | $45.81 M(<-9900.0%) | $46.43 M(<-9900.0%) |
| Jun 2017 | - | -$104.00 K(-106.4%) | -$387.00 K(-11.0%) |
| Mar 2017 | - | $1.64 M(-278.3%) | -$435.00 K(-80.0%) |
| Dec 2016 | -$2.17 M(-107.6%) | -$917.00 K(-8.4%) | -$2.17 M(-108.0%) |
| Sep 2016 | - | -$1.00 M(+558.6%) | $26.99 M(-3.5%) |
| Jun 2016 | - | -$152.00 K(+50.5%) | $27.96 M(-0.7%) |
| Mar 2016 | - | -$101.00 K(-100.4%) | $28.14 M(-1.1%) |
| Dec 2015 | $28.45 M(-41.1%) | $28.24 M(<-9900.0%) | $28.45 M(+490.4%) |
| Sep 2015 | - | -$32.00 K(-194.1%) | $4.82 M(-89.7%) |
| Jun 2015 | - | $34.00 K(-83.0%) | $46.65 M(-4.0%) |
| Mar 2015 | - | $200.00 K(-95.7%) | $48.59 M(+0.6%) |
| Dec 2014 | $48.30 M(+500.2%) | $4.62 M(-89.0%) | $48.30 M(+9.3%) |
| Sep 2014 | - | $41.80 M(+2016.3%) | $44.19 M(+1745.4%) |
| Jun 2014 | - | $1.98 M(-2508.5%) | $2.39 M(-70.0%) |
| Mar 2014 | - | -$82.00 K(-116.3%) | $7.97 M(-0.9%) |
| Dec 2013 | $8.05 M(-9.4%) | $501.70 K(>+9900.0%) | $8.05 M(+6.6%) |
| Sep 2013 | - | $0.00(-100.0%) | $7.55 M(0.0%) |
| Jun 2013 | - | $7.55 M(<-9900.0%) | $7.55 M(<-9900.0%) |
| Mar 2013 | - | -$7900.00 | -$7900.00 |
| Dec 2012 | $8.88 M | - | - |
FAQ
- What is Marinus Pharmaceuticals annual cash flow from financing activities?
- What is the all time high annual CFF for Marinus Pharmaceuticals?
- What is Marinus Pharmaceuticals annual CFF year-on-year change?
- What is Marinus Pharmaceuticals quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Marinus Pharmaceuticals?
- What is Marinus Pharmaceuticals quarterly CFF year-on-year change?
- What is Marinus Pharmaceuticals TTM cash flow from financing activities?
- What is the all time high TTM CFF for Marinus Pharmaceuticals?
- What is Marinus Pharmaceuticals TTM CFF year-on-year change?
What is Marinus Pharmaceuticals annual cash flow from financing activities?
The current annual CFF of MRNS is $26.63 M
What is the all time high annual CFF for Marinus Pharmaceuticals?
Marinus Pharmaceuticals all-time high annual cash flow from financing activities is $124.74 M
What is Marinus Pharmaceuticals annual CFF year-on-year change?
Over the past year, MRNS annual cash flow from financing activities has changed by -$98.11 M (-78.65%)
What is Marinus Pharmaceuticals quarterly cash flow from financing activities?
The current quarterly CFF of MRNS is -$1.93 M
What is the all time high quarterly CFF for Marinus Pharmaceuticals?
Marinus Pharmaceuticals all-time high quarterly cash flow from financing activities is $94.14 M
What is Marinus Pharmaceuticals quarterly CFF year-on-year change?
Over the past year, MRNS quarterly cash flow from financing activities has changed by $0.00 (0.00%)
What is Marinus Pharmaceuticals TTM cash flow from financing activities?
The current TTM CFF of MRNS is -$18.70 M
What is the all time high TTM CFF for Marinus Pharmaceuticals?
Marinus Pharmaceuticals all-time high TTM cash flow from financing activities is $124.74 M
What is Marinus Pharmaceuticals TTM CFF year-on-year change?
Over the past year, MRNS TTM cash flow from financing activities has changed by $0.00 (0.00%)